Source comparison
CJC-1295 no DAC & Ipamorelin for Synergistic GH Release: Protocol Comparison
Researchers designing growth hormone modulation studies face a choice between monotherapy (single peptide), dual therapy (CJC-1295 no DAC & Ipamorelin for synergistic GH release), and alternative secretagogues like Sermorelin or MK 677. Each approach produces
This comparison does not assign a generated winner or score.
- Researchers designing growth hormone modulation studies face a choice between monotherapy (single peptide), dual therapy (CJC-1295 no DAC & Ipamorelin for synergistic GH release), and alternative secretagogues like Sermorelin or MK 677. Each approach produces different secretory patterns, dosing frequencies, and receptor engagement profiles.
- CJC-1295 no DAC alone
- GHRH receptor agonist; increases pulse amplitude
- 100–200 mcg 1–3×/day
- Sharp peaks, 30-min half-life, returns to baseline in 2–3 hrs
- Mimics endogenous pulsatile rhythm without somatostatin suppression
- Effective for amplitude but leaves ghrelin pathway untouched. Monotherapy limits ceiling
- Ipamorelin alone
- Selective GHS-R1a agonist; suppresses somatostatin, mild GH stimulation
- 100–300 mcg 1–3×/day
- Moderate peaks, frequency-dependent
- No cortisol/prolactin elevation; cleanest ghrelin mimetic profile
- Gentle and selective but lacks GHRH-driven amplitude. Better for sensitivity than magnitude
- CJC-1295 no DAC + Ipamorelin
- Dual pathway: GHRH + ghrelin receptor co-activation
- 100–200 mcg each, 1–3×/day
- Synergistic peaks 3–5× monotherapy amplitude
- Functional synergy. Both amplitude and somatostatin suppression in one protocol
- Gold standard for pulsatile GH research. Highest magnitude, shortest administration window
- Sermorelin
- GHRH analog, similar to CJC but shorter half-life (~5 min)
- 200–500 mcg before bed
- Single nocturnal pulse, very brief
- Lowest cost; well-studied safety profile
- Requires higher doses and offers no advantage over CJC-1295 no DAC in pulsatile precision
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic, 24-hr half-life
- 10–25 mg once daily
- Sustained elevation, not pulsatile
- Oral administration, once-daily dosing
- Chronic elevation risks desensitization and insulin resistance. Lacks physiological pulse structure
- The comparison makes the case for dual-pathway activation clear: CJC-1295 no DAC & Ipamorelin for synergistic GH release produces the highest-magnitude pulses while maintaining the physiological rhythm that prevents receptor downregulation. Monotherapy protocols are simpler but mechanistically incomplete.